Itralase SB 130mg Capsule contains itraconazole, a broad-spectrum antifungal agent used for the treatment of various fungal infections. Itraconazole belongs to the triazole class of antifungals and works by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes, thereby disrupting membrane integrity and leading to fungal cell death. This medication is indicated for the management of systemic and superficial mycoses, including aspergillosis, blastomycosis, histoplasmosis, onychomycosis, and candidiasis. Itralase SB 130mg Capsule is typically administered orally and should be taken with food to enhance absorption. The dosage and duration of therapy depend on the type and severity of the infection, as well as patient-specific factors such as age and renal or hepatic function. Common adverse effects may include gastrointestinal disturbances, headache, dizziness, and rash. Caution is advised in patients with liver impairment, and periodic monitoring of liver function tests is recommended during prolonged therapy. Itraconazole has potential drug interactions due to its effect on cytochrome P450 enzymes; therefore, concomitant use with certain medications should be avoided or closely monitored. Itralase SB 130mg Capsule should be used under medical supervision to ensure safety and efficacy.